Latest Breaking News On - Heather savelle - Page 6 : comparemela.com

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors

TSC-200-A0201 is TScan’s third cleared IND for the T-Plex solid tumor program supporting the use of multiple TCRs in combination to deliver customized, multiplexed TCR-T cell therapies based on. | June 6, 2023

Debora bartonHeather savelleGavin macbeathJoyce allaireCompany immunobankDrug administrationGlobe newswire tscan therapeutics incSecurities exchangeLifesci advisorsTscan therapeutics incChief medicalChief executive officerPrivate securities litigation reform actSecurities exchange actFinancial conditionAnnual report

TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting

WALTHAM, Mass., June 01, 2023 TScan Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of T cell receptor -engineered T cell therapies for the treatment. | June 1, 2023

United statesMccormick placeHeather savelleJoyce allaireShrikanta chattopadhyayLifesci advisorsTscan therapeutics incAmerican society of clinical oncologyGlobe newswire tscan therapeutics incClinical oncologyAnnual meetingBoard numberDevelopmental therapeuticsSci advisorsTscan therapeuticsNc stock exchange

TScan Therapeutics Announces Pricing of $140 Million Public Offering

TScan Therapeutics Announces Pricing of $140 Million Public Offering
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesWedbush pacgrowHeather savelleJoyce allaireLos angelesExchange commissionSecurities exchangeLifesci advisorsMorgan stanleyWedbush securities incMorgan stanley coTscan therapeutics incProspectus departmentPrivate securities litigation reform actAnnual report

TScan Therapeutics Announces Launch of Proposed Public Offering

WALTHAM, Mass., May 25, 2023 TScan Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of T cell receptor -engineered T cell therapies for the treatment. | May 25, 2023

New yorkUnited statesJoyce allaireHeather savelleLos angelesWedbush pacgrowTscan therapeutics incProspectus departmentLifesci advisorsMorgan stanley coExchange commissionGlobe newswire tscan therapeutics incMorgan stanleySecurities exchangeWedbush securities incPrivate securities litigation reform act

TScan Therapeutics Appoints Gavin MacBeath, Ph D as Chief Executive Officer and as a Member of the Board of Directors

WALTHAM, Mass., May 24, 2023 TScan Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of T cell receptor -engineered T cell therapies for the treatment. | June 11, 2023

Timothy barberichGavin macbeathJoyce allaireHeather savelleSecurities exchangeLifesci advisorsUniversity of manitobaPrincipal investigator at harvard medical schoolHarvard bauer centerGenomics researchDiscovery at merrimack pharmaceuticalsStuart schreiber at harvard universityTscan therapeutics incScripps research instituteGlobe newswire tscan therapeutics incChief executive officer